Publication: Management of Pharmacologic Adverse Effects in Advanced Liver Disease.
| dc.contributor.author | Garcia-Cortes, Miren | |
| dc.contributor.author | Garcia-Garcia, Alberto | |
| dc.date.accessioned | 2023-05-03T14:25:25Z | |
| dc.date.available | 2023-05-03T14:25:25Z | |
| dc.date.issued | 2022-06 | |
| dc.description.abstract | As a consequence of the altered hepatic architecture in advanced liver disease, drug metabolism is modified by changes in pharmacokinetic and pharmacodynamic properties, leading to the appearance of adverse effects and drug interactions and increasing the risk of over- or underdosing of medications. However, there are no tests that accurately determine the degree of impairment of liver metabolic function; therefore, general recommendations are established based on the degree of hepatic extraction, degree of hepatic metabolism, and degree of protein binding. Although the hepatic toxicity of some frequently used drugs, such as acetaminophen, is well known, many health care professionals are unaware or not fully aware of the deleterious effects that other drugs can have on patients with advanced liver injury, as is the case for nonsteroidal anti-inflammatory drugs. It is very important to increase awareness among both health care professionals and patients with advanced liver disease to limit the use of inappropriate drugs and prevent drug-induced liver injury. | |
| dc.description.version | Si | |
| dc.identifier.citation | García-Cortés M, García-García A. Management of Pharmacologic Adverse Effects in Advanced Liver Disease. Clin Drug Investig. 2022 Jun;42(Suppl 1):33-38. | |
| dc.identifier.doi | 10.1007/s40261-022-01150-w | |
| dc.identifier.essn | 1179-1918 | |
| dc.identifier.pmc | PMC9205818 | |
| dc.identifier.pmid | 35522395 | |
| dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205818/pdf | |
| dc.identifier.unpaywallURL | https://link.springer.com/content/pdf/10.1007/s40261-022-01150-w.pdf | |
| dc.identifier.uri | http://hdl.handle.net/10668/21630 | |
| dc.issue.number | Suppl 1 | |
| dc.journal.title | Clinical drug investigation | |
| dc.journal.titleabbreviation | Clin Drug Investig | |
| dc.language.iso | en | |
| dc.organization | Hospital Universitario Virgen de la Victoria | |
| dc.organization | Instituto de Investigación Biomédica de Málaga-IBIMA | |
| dc.page.number | 33-38 | |
| dc.provenance | Realizada la curación de contenido 30/09/2025. | |
| dc.publisher | Adis International Ltd. | |
| dc.pubmedtype | Journal Article | |
| dc.pubmedtype | Review | |
| dc.relation.publisherversion | https://dx.doi.org/10.1007/s40261-022-01150-w | |
| dc.rights | Attribution-NonCommercial 4.0 International | |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
| dc.subject | Advanced liver disease | |
| dc.subject | Altered hepatic architecture | |
| dc.subject | Drug interactions | |
| dc.subject | NSAIDs hepatotoxicity | |
| dc.subject | Patient education | |
| dc.subject.decs | Enfermedad hepática crónica | |
| dc.subject.decs | Cirrosis hepática | |
| dc.subject.decs | Metabolismo de medicamentos | |
| dc.subject.decs | Farmacocinética | |
| dc.subject.decs | Farmacodinamia | |
| dc.subject.decs | Efectos adversos de los medicamentos | |
| dc.subject.decs | Interacciones de medicamentos | |
| dc.subject.decs | Acetaminofén | |
| dc.subject.decs | Hepatotoxicidad | |
| dc.subject.decs | Lesión hepática inducida por fármacos | |
| dc.subject.mesh | Acetaminophen | |
| dc.subject.mesh | Chemical and Drug Induced Liver Injury | |
| dc.subject.mesh | Drug Interactions | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Liver | |
| dc.subject.mesh | Liver Diseases | |
| dc.title | Management of Pharmacologic Adverse Effects in Advanced Liver Disease. | |
| dc.type | review | |
| dc.type.hasVersion | VoR | |
| dc.volume.number | 42 | |
| dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1

